Damir Begic
About Damir Begic
Damir Begic is the Team Lead/Director of HCC and Hematology - Oncology Clinical Science at Bristol Myers Squibb in Summit, New Jersey, with extensive experience in oncology clinical development and global regulatory interactions.
Current Role at Bristol Myers Squibb
Damir Begic currently serves as Team Lead/Director of HCC and Hematology - Oncology Clinical Science at Bristol Myers Squibb. He is based in Summit, New Jersey, United States. Damir's role involves overseeing clinical science initiatives and leading development programs in hepatocellular carcinoma (HCC) and hematology-oncology.
Previous Roles at Bristol Myers Squibb
From 2016 to 2020, Damir Begic worked at Bristol Myers Squibb as Medical Monitor/Director of Oncology Global Clinical Development in Princeton, NJ. During this tenure, he contributed to various oncology clinical development projects, ensuring the safety and efficacy of experimental therapies through rigorous clinical monitoring.
Experience at Celgene
Damir Begic was employed at Celgene from 2013 to 2016 as Associate Director/Senior Clinical Research Scientist in the Solid Tumors Division, located in Summit. His responsibilities included managing and conducting clinical research for solid tumor cancer therapies, ensuring adherence to regulatory standards and scientific excellence.
Roles at Novartis
Damir Begic held multiple positions at Novartis between 2007 and 2013. He started as a Post-Doctoral Fellow focused on PK/PD in oncology and infectious diseases. He then progressed to Senior Clinical Manager and later Expert Clinical Manager in Oncology Global Clinical Development. His work spanned both U.S. and Swiss locations, where he managed global clinical trials and development projects.
Educational Background
Damir Begic earned his Doctor of Pharmacy (Pharm.D.) from Duquesne University, completing his studies from 2001 to 2007. His education provided a strong foundation in pharmaceutical sciences, preparing him for a career in clinical research and drug development.
Clinical Trials and Global Regulatory Experience
Damir Begic has extensive experience in global regulatory interactions, including participation in the Oncologic Drugs Advisory Committee (ODAC). He has led the development and execution of first-in-human (FIH) and registrational Phase III trials, contributing significantly to advancing clinical science in oncology.
Business Development and Due Diligence
In addition to his clinical roles, Damir Begic is skilled in business development and due diligence. He has evaluated external assets for licensing, clinical collaborations, and mergers and acquisitions (M&A), ensuring strategic growth and innovation within the organizations he has served.
Clinical Trials in Asia-Pacific Region
Damir Begic has experience in developing and conducting clinical trials in the Asia-Pacific (APAC) region. This includes managing submissions and co-development with local partners, demonstrating his capability in navigating diverse regulatory landscapes and fostering international collaborations.